Manipulation of costimulatory signals to enhance antitumor T-cell responses
Authors:
- 1 October 1995
- journal article
- review article
- Published by Elsevier in Current Opinion in Immunology
- Vol. 7 (5) , 682-686
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy?Immunology Today, 1995
- Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice.Journal of Experimental Medicine, 1995
- Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptorsImmunity, 1994
- CTLA-4 can function as a negative regulator of T cell activationImmunity, 1994
- The B7 and CD28 receptor familiesImmunology Today, 1994
- Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor AntigensScience, 1994
- Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.Journal of Experimental Medicine, 1994
- In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression.Journal of Experimental Medicine, 1994
- Effective Tumor Vaccine Generated by Fusion of Hepatoma Cells with Activated B CellsScience, 1994
- Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma CellsScience, 1993